Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine K Matthay

Showing results (1-10 of 189) with videos related to

Pageof 19
Sort By:
The Lancet. Oncology|November 17, 2018
Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?Katherine K Matthay
The Lancet. Oncology|March 1, 2008
Chemotherapy for neuroblastoma: does it hit the target?Katherine K Matthay
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorptionKatherine K Matthay
Pediatric Blood & Cancer|November 2, 2005
Is liver metastasis in neuroblastoma an indication for treatment reduction?Katherine K Matthay
Nature Reviews. Clinical Oncology|May 25, 2022
Advancing therapy for neuroblastomaBo Qiu, Katherine K Matthay
Current Oncology Reports|October 21, 2009
Neuroblastoma: biology and stagingSabine Mueller, Katherine K Matthay
Nuclear Medicine and Biology|December 4, 2008
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaSteven G DuBois, Katherine K Matthay
Paediatric Drugs|March 24, 2004
Neuroblastoma: evolving therapies for a disease with many facesRobert E Goldsby, Katherine K Matthay
Expert Review of Neurotherapeutics|September 30, 2011
Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastomaWilliam Clay Gustafson, Katherine K Matthay
Cell and Tissue Research|March 25, 2018
Neuroblastoma: clinical and biological approach to risk stratification and treatmentVanessa P Tolbert, Katherine K Matthay
Pageof 19

Showing results (1-10 of 189) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|November 17, 2018
Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?Katherine K Matthay
The Lancet. Oncology|March 1, 2008
Chemotherapy for neuroblastoma: does it hit the target?Katherine K Matthay
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorptionKatherine K Matthay
Pediatric Blood & Cancer|November 2, 2005
Is liver metastasis in neuroblastoma an indication for treatment reduction?Katherine K Matthay
Nature Reviews. Clinical Oncology|May 25, 2022
Advancing therapy for neuroblastomaBo Qiu, Katherine K Matthay
Current Oncology Reports|October 21, 2009
Neuroblastoma: biology and stagingSabine Mueller, Katherine K Matthay
Nuclear Medicine and Biology|December 4, 2008
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaSteven G DuBois, Katherine K Matthay
Paediatric Drugs|March 24, 2004
Neuroblastoma: evolving therapies for a disease with many facesRobert E Goldsby, Katherine K Matthay
Expert Review of Neurotherapeutics|September 30, 2011
Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastomaWilliam Clay Gustafson, Katherine K Matthay
Cell and Tissue Research|March 25, 2018
Neuroblastoma: clinical and biological approach to risk stratification and treatmentVanessa P Tolbert, Katherine K Matthay
Pageof 19